Desde el diagnóstico bioquímico al diagnóstico clínico | 18 JUN 19

Manifestaciones cutáneas de la resistencia a la insulina

La resistencia a la insulina es una característica bioquímica patognomónica de la obesidad y la diabetes. Sus manifestaciones cutáneas ofrecen una manera fiable y fácil de detectarla
Autor: González-Saldivar G, Rodríguez-Gutiérrez R . Ocampo-Candiani J . Dermatol Ther (Heidelb) (2017) 7:37–51
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas
Referencias bibliográficas: 

1. Boyle J, Thompson T, Gregg E, Barker L, Williamson D. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:1.

2. Moller DE, Flier JS. Insulin resistance— mechanisms, syndromes, and implications. N Engl J Med. 1991;325:938–48.

3. Jung U, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184–223. 4. Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. Sci World J. 2015. doi:10.1159/000245731.

5. Yamazaki H, Ito S, Yoshida H. Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children. Pediatr Int. 2003;45:701–5.

6. Mukhtar Q, Cleverley G, Voorhees RE, McGrath JW. Prevalence of acanthosis nigricans and its association with hyperinsulinemia in New Mexico adolescents. J Adolesc Health. 2001;28:372–6.

7. Edgerton DS, et al. Insulin’ s direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006;116:521–7.

8. Shanik MH, et al. Insulin resistance and hyperinsulinemia: Is hyperinsulinemia the cart or the horse? Diabet Care. 2008;31:262–8.

9. Hermanns-Leˆ T, Scheen A, Pie´rard GE. Acanthosis nigricans associated with insulin resistance. Am J Clon Dermatol. 2004;5:199–203.

10. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56:901–16.

11. Barbato M, et al. Association of acanthosis nigricans and skin tags with insulin resistance. An Bras Dermatol. 2012;87:97–104.

12. Cordain L, Eades MR, Eades MD. Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol. 2003;136:95–112.

13. Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus. a review. Endocrinol Metab Clin N Am. 2013;42:869–98.

14. El Safoury OS, Ibrahim M. A clinical evaluation of skin tags in relation to obesity, type 2 diabetis mellitus, age, and sex. Indian J Dermatol. 2011;56:393–7. 15. Sari R, Akman A, Alpsoy E, Balci MK. The metabolic profile in patients with skin tags. Clin Exp Med. 2010;10:193–7.

16. Rasi A, Soltani-Arabshahi R, Shahbazi N. Skin tag as a cutaneous marker for impaired carbohydrate metabolism: a case–control study. Int J Dermatol. 2007;46:1155–9.

17. Demir S, Demir Y. Acrochordon and impaired carbohydrate metabolism. Acta Diabetol. 2002;39:57–9.

18. Schilling WH, Crook MA. Cutaneous stigmata associated with insulin resistance and increased cardiovascular risk. Int J Dermatol. 2014;53:1062–9.

19. Margolis J, Margolis LS. Skin tags-a frequent sign of diabetes mellitus. N Engl J Med. 1976;294:1184.

20. Kahana M, et al. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol. 1987;67:175–7.

21. Behm B, Schreml S, Landthaler M, Babilas P. Skin signs in diabetes mellitus. J Eur Acad Dermatol Venereol. 2012;26:1203–11.

22. Men J, Boberg J. Fibroepithelial polyps. An unusual case report. J Am Podiatr Med Assoc. 1990;80:496–8.

23. Kamino H, Reddy VB, Pui J. Dermatology. Philadelphia: Elsevier; 2012. p. 1961.

24. Brinster NK, Liu V, Diwan AH, McKee PH. Dermatopathology: high-yield pathology. Edinburgh: Elsevier; 2011. p. 446.

25. Pfenninger JL. Pfenninger and Fowler’s Procedures for Primary Care. Philadelphia: Elsevier; 2011. p. 69–84.

26. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol. 2007;57:502–8.

27. Dobrev D. Case of acanthosis nigricans associated with gastric cancer. Suvr Med. 1958;9:100–3.

28. Lindewall G. Acanthosis nigricans associated with carcinoma of the stomach: a case report. Acta Derm Venereol. 1960;40:493–9.

29. Pollitzer S. Acanthosis nigricans: a symptom of a disorder of the abdominal sympathetic. JAMA. 1909;53:1369–73.

30. Janovsky V. Acanthosis nigricans. In: Unna PG, Morris M, Besnier E, editors. International atlas of rare skin diseases. London: HK Lewis & Co; 1891. p. 4–5.

31. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabet Care. 1999;22:1655–9.

32. Go´mez-Flores M, et al. Implications of a clinically ignored site of acanthosis nigricans: the knuckles. Exp Clin Endocrinol Diabet. 2014;123:27–33.

33. Kluczynik C, et al. Acanthosis nigricans and insulin resistance in overweight children and adolescents. An Bras Dermatol. 2012;87:531–7.

34. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med. 1989;87:269–72.

35. Mun˜oz-Pe´rez MA, Camacho F. Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome. J Eur Acad Dermatol Venereol. 2001;15:325–7.

36. Kong AS, et al. Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in Southwestern US primary care practices. Ann Fam Med. 2007;5:202–8.

37. Matsuoka LY, Wortsman J, Goldman J. Acanthosis Nigricans. Clin Dermatol. 1993;11:21–5.

38. Puri N. A study of pathogenesis of acanthosis nigricans and its clinical implications. Indian J Dermatol. 2011;56:678–83.

39. Phiske MM. An approach to acanthosis nigricans. Indian Dermatol Online J. 2014;5:239–49.

40. Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol. 1991;127:1139–40.

41. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J. 2008;14:2.

42. Adigun C, Pandya A. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. J Eur Dermatol Venereol. 2009;23:486–7. 43. Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis. 2003;71:33–4.

44. Sperling LC, SInclair R, Shabrawi-Caelen L. Dermatology. Philadelphia: Elsevier; 2012. p. 1093–8.

45. Gonzalez-Gonzalez JG, Mancillas-Adame LG, Fernandez-Reyes M, Lavalle-Gonzalez FJ, Ocampo-Candiani J. Androgenetic alopecia and insulin resistance in young men. Clin Endocrinol. 2009;71:494–9.

46. Blume-Peytavi U, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164:5–15.

47. Olsen EA, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52:301–11.

48. Severi G, et al. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br J Dermatol. 2003;149:1207–13.

49. Nabaie L, et al. Androgenic alopecia and insulin resistance: are they really related? Clin Exp Dermatol. 2009;34:694–7.

50. Matilainen V, Koskela P, Keina¨nen-Kiukaanniemi S. Early androgenetic alopecia as a marker of insulin resistance. Lancet. 2000;356:1165–6.

51. Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol. 2013;79:613–25.

52. Otberg N, Finner AM, Shapiro J. Androgenetic Alopecia. Endocrinol Metab Clin N Am. 2007;36:379–98.

53. Sawaya M, Shalita A. Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J Cutan Med Surg. 1998;3:9–15.

54. Bakry O, Shoeib MA, El Shafiee M, Hassan A. Androgenetic alopecia, metabolic syndrome, and insulin resistance: is there any association? A case-control study. Indian Dermatol Online J. 2014;5:276–91.

55. Trieu N, Eslick GD. Alopecia and its association with coronary heart disease and cardiovascular risk factors: a meta-analysis. Int J Cardiol. 2014;176:687–95. 56. SInclair R. Male pattern androgenetic alopecia. BMJ. 1998;317:865–9.

57. Su L-H, Chen L-S, Lin S-C, Chen H-H. Association of androgenetic alopecia with mortality from diabetes mellitus and heart disease. JAMA Dermatol. 2013;149:601–6.

58. Tosti A, Torres F. Dermoscopy in the diagnosis of hair and scalp disorders. Actas Dermosifiliogr. 2009;100:114–9.

59. Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9:1–57. 60. Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999;141:398–405.

61. Dumitrescu R, Mehedintu C, Briceag I, Purcarea V, Hudita D. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life. 2015;8:142–5.

62. Jeffcoate W, Kong M-F. Diabe`te des femmes a` barbe: a classic paper reread. Lancet. 2000;356:1183–5.

63. Vryonidou A, Paschou S, Muscogiuri G, Orio F, Goulis D. Metabolic Syndrome through the females life cycle. Eur J Endocrinol. 2015;1:153.

64. Poretsky L, Piper B. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obs Gynecol. 1994;84:613–21.

65. Housman E, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists Part I. Diagnosis and manifestations. J Am Acad Dermatol. 2014;71:847-e1.

66. Knochenhauer E, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078–82.

67. Ferriman D, Gallwey J. Clinical assessment of body hair in women. J Clin Endocrinol Metab. 1961;21:1440–7.

68. Rosenfield RL. Hirsutism. NEJM. 2005;24:2578–88.

69. Claman P. SOGC clinical practice guidelines. Hirsutism: evaluation and treatment. J Obs Gynaecol Can. 2002;24:62–73.

70. Hohl A, Ronsoni MF, Oliveira M. Hirsutism: diagnosis and treatment. Arq Bras Endocrinol Metab. 2014;58:97–107.

71. Azziz R, et al. Criteria for defining polycyctic ovary syndrome as a predominantly hyperandrogenetic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91:4237–45.

72. Melnik BC, John SM, Plewig G. Acne: risk indicator for increased body mass index and insulin resistance. Acta Derm Venereol. 2013;93:644–9.

73. Demir B, et al. Changes in serum desnutrin levels in patients with acne vulgaris. Eur J Dermatol. 2014;24:589–93.

74. Monfrecola G, et al. Mechanistic target of rapamycin (mTOR) expression is increased in acne patients’ skin. Exp Dermatol. 2016;25:153–5.

75. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.

76. Buzney E, Sheu J, Buzney C, Reynolds R. Polycystic ovary syndrome: A review for dermatologists: Part II. Treatment. J Am Acad Dermatol. 2014;71:859-e1.



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí